Jaguar Health, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Lisa A. Conte
- Full Time Employees
- 47
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 200 Pine Street San Francisco CA United States of America 94104
- IPO Date
- May 12, 2015
- CIK
- 0001585608
- Website
- jaguar.health
- Similar Companies
- Business
- Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company that develops and commercializes novel, plant-based, non-opioid prescription medicines derived from rainforest plants for gastrointestinal distress in people and animals, including chronic debilitating diarrhea, urgency, incontinence, and cramping; it operates through Human Health and Animal Health segments targeting companion animals, production animals, HIV/AIDS patients on antiretroviral therapy, and cancer patients. The company offers Mytesi (crofelemer 125 mg delayed-release tablets), an FDA-approved anti-secretory antidiarrheal for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; Canalevia-CA1 (crofelemer delayed-release tablets), an FDA-conditionally approved prescription product for chemotherapy-induced diarrhea in dogs; and Neonorm products for calves and foals; its pipeline includes crofelemer in Phase III trials for prophylaxis of cancer therapy-related diarrhea (OnTarget trial topline results expected forthcoming) and Phase II/III for rare diseases such as short bowel syndrome and microvillus inclusion disease, as well as irritable bowel syndrome, idiopathic diarrhea, and NP-300 in Phase I for moderate-to-severe diarrhea. Founded in 2013 and headquartered in San Francisco, California, Jaguar conducts operations primarily in the United States with expansion efforts in Europe via Napo Therapeutics, an Italian subsidiary established in 2021, and supports investigator-initiated studies in the US, EU, and Middle East/North Africa; it maintains strategic relationships including a joint venture, Magdalena Biosciences, with Filament Health for mental health indications, an exclusive distribution agreement for Gelclair, and recent financial activities such as a $1.5 million registered direct offering in May 2025 and a submission to the European Medicines Agency in December 2025 regarding an EU approval pathway for Canalevia.
Company News
Jaguar Health Provides Update Regarding Special Stock Dividend
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
Jaguar Health Announces a Special Stock Dividend
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float
Jaguar Health Stock Surges Friday: What's Happening?
Jaguar Health Stock Slides Thursday: What's Happening?
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%
Two Biotechs Get Beaten Down: Jaguar Health Collapses 59%, Viking Therapeutics Sinks 4%
Jaguar Health Stock Plunges Wednesday: What's Happening?
Jaguar Health Receives Fee Waivers from FDA
Jaguar Health, Inc. Announces Reverse Stock Split
Jaguar Health Stock Slides Thursday: What's Happening?
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Jaguar Health, Inc. (JAGX) Q2 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health Reports Second Quarter 2026 Financials